Skip to content

Comparative Evaluation of the Effect of Different Adjunctive Air Polishing Powders in Nonsurgical Periodontal Therapy in Patients with Stage II and III Periodontitis

Comparative Evaluation of the Effect of Different Adjunctive Air Polishing Powders in Nonsurgical Periodontal Therapy in Patients with Stage II and III Periodontitis: (A Randomized Controlled Clinical Trial)

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06726902
Acronym
GBT
Enrollment
56
Registered
2024-12-10
Start date
2024-03-03
Completion date
2024-12-31
Last updated
2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Keywords

GBT, Periodontitis, SI

Brief summary

The aim of this clinical trial is to evaluate and compare the effect of a newly designed air-polishing device (APD) using Erythritol, Glycine, and Trehalose air-polishing powders in nonsurgical periodontal therapy with control (conventional scaling and root planning) following the concept of guided biofilm therapy (GBT) as an adjunctive to subgingival instrumentation (SI) in nonsurgical periodontal therapy for Stage II and III periodontitis patients both clinically and microbiologically.

Interventions

DEVICEGBT and SI with erythritol powder

Non-Surgical Periodontal treatment: 1. Guided Biofilm Therapy * Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. * Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with erythritol powder . 2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only.

OTHERGBT and SI with glycine powder

Non-Surgical Periodontal treatment: 1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with glycine powder. 2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only

OTHERGBT and SI with trehalose powder

Non-Surgical Periodontal treatment: 1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with trehalose powder . 2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only

OTHERSRP and SI

conventional scaling and root planning (SRP) with subgingival instrumentation only will be performed

Sponsors

Diana Ibrahim
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Individuals of both sexes with an age between 30 and 65 years, having at least 16 natural teeth in function, 2. Stage II and III (moderate to severe) periodontitis, having at least 16 teeth with the need for SI 3. Interproximal plaque index (API) ≤ 35%; patients with Good oral hygiene. 4. No history of systemic disease that may influence periodontal disease

Exclusion criteria

1. Pregnancy or breastfeeding, 2. Smokers with more than seven cigarettes per day 3. Patients that had a treatment with antibiotics within six months before the study 4. Need for periodontal surgery or adjunctive antibiotic treatment to the SI 5. Patients who had any periodontal treatment during the last year before the study. 6. Patients with known systemic or autoimmune disease.

Design outcomes

Primary

MeasureTime frameDescription
Bleeding on probingup to six months
Pain Assessmentup to six monthsPain level will be assed using Visual Analogue Scale (VAS) from 1 (minimum) to 10 (maximum)
Probing depthup to six months
Plaque accumulationup to six months
Clinical attachment levelup to six months
Microbiological Assessment of Aggregatibacter actinomycetemcomitans (Aa)one month
Microbiological Assessment of Porphyromonas gingivalis (Pg)one month
Microbiological Assessment of Tannerella forsythia (Tf)one month
Microbiological Assessment of Treponema denticola (Td)one month

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026